Abstract
Alzheimers Dement. 2025 Dec;21 Suppl 7:e108520. doi: 10.1002/alz70861_108520.
ABSTRACT
BACKGROUND: As fully automated instruments for plasma biomarkers for Alzheimer's disease (AD) are being implemented in specialist clinics, many are questioning whether they can be used interchangeably with, or as substitutes for, gold-standard cerebrospinal fluid (CSF) biomarkers. We aimed to compare fully automated Lumipulse plasma assays that are under FDA evaluation with FDA-approved CSF assays.
METHOD: We included patients with subjective cognitive decline, mild cognitive impairment, and dementia from the BioFINDER-Memory Clinic (n =122), BioFINDER-Primary Care (n =169) and ADNI (n =165) cohorts, in which plasma p -tau217 and plasma Aβ42 were measured with Lumipulse assays (Table 1). Plasma biomarkers were compared with CSF Aβ42/Aβ40 (Lumipulse) in the BioFINDER cohorts and CSF p -tau181/Aβ42 (Elecsys) in ADNI. Previously published one- and two-cutoff approaches were used for the biomarkers. The two-cutoff approach applies upper (positivity) and lower (negativity) cutoffs with intermediate cases being those with results in between the cutoffs (excluded in the analyses). The outcome was presence of AD pathology (visual read Aβ-PET).
RESULT: Plasma p -tau217 identified AD pathology with AUCs of 0.95 (memory clinic), 0.89 (primary care) and 0.94 (ADNI). For p -tau217/Aβ42, AUCs of 0.95 (memory clinic), 0.90 (primary care), and 0.92 (ADNI) were observed (Figure 1B,E,H). CSF performed similar in BioFINDER (AUCs 0.91-0.92; all p >0.304) and better in ADNI (AUC 0.98, p =0.032). When applying one cutoff, plasma p -tau217 and p -tau217/Aβ42 had higher accuracies than CSF Aβ42/Aβ40 in BioFINDER-Memory Clinic (80-91%, all p <0.024) (Figure 1A), while performances were similar in BioFINDER-Primary Care (80-83%, all p >0.488, Figure 1D) and ADNI (88-92%, all p >0.152, Figure 1G). With two cutoffs, no significant differences between plasma p -tau217 (92%) or plasma p -tau217/Aβ42 (91%) and CSF biomarkers (89-93%) were observed in BioFINDER-Memory Clinic or ADNI (Figure 2A,G). In primary care, plasma p -tau217 (86%), but not p -tau217/Aβ42 (90%), had lower accuracy than CSF Aβ42/Aβ40 (92%, p =0.028; Figure 2E).
CONCLUSION: Plasma p -tau217 and p -tau217/Aβ42 Lumipulse demonstrated similar or slightly inferior performance compared with FDA-approved CSF tests for detecting AD pathology across three cohorts, including primary care. Since these plasma assays are under FDA-review for AD diagnosis, the results are essential for validating their performance relative to CSF biomarkers. Additional comparisons will be presented at AAIC.
PMID:41434844 | DOI:10.1002/alz70861_108520
UK DRI Authors
